POSTPONED UNTIL FURTHER NOTICE
Enforcement strategies. Inspections and recalls. Self-regulation and best practices. New whistleblowing policies. New data you’re required to collect and maintain. What “quality” will mean going forward. All that — and more — will be revealed Thursday, March 23, 2017, at this top-level sit-down with the men and women who oversee your drugs and devices.
You'll hear from Washington insiders and former top FDA officials about what to expect from the Trump Administration on enforcement. Will it be business as usual, radical changes, or something in between?
And you’ll discover:
✓New FDA enforcement initiatives that could affect your market position ...
✓New thinking on FDA penalties and how to avoid them ...
✓New approaches to reducing the likelihood of inspection visits ...
✓New information on the push for more structured whistleblowing ...
Prepare to dive deep into regulatory policy details. Take the move to new “dashboards” and compliance tools. This shift in FDA direction is evolving so rapidly, many drug and device makers are having trouble keeping up. How are these new initiatives meshing, and what will the impact be on inspections and enforcement? Come to the briefing and find out.
The event takes place in the conference rooms of Arent Fox LLP, a top Washington law firm specializing in FDA regulatory matters. The host and moderator is Counsel Brian Malkin, of Arent Fox’s FDA regulatory team.
Every presidential election is a turning point, this one maybe more than any other. You owe it to your colleagues — and to yourself — to come to Washington now and make ready for all the uncertainties and unknowns that may lie ahead.
Host and Moderator
Counsel, Arent Fox LLP
Who will benefit?